Sun purges 18 Ranbaxy execs in integration move

Weeks after Sun Pharmaceutical completed its acquisition of troubled Ranbaxy Laboratories, 18 top execs have reportedly been given their pink slips. The Economic Times reports that executives let go include President and CFO Indrajit Banerjee and Yugal Sikri, who headed operations in India. A source said another 150 executives would be terminated as the company continues its integration. Sun has said its top priority is to restore the rights of four Ranbaxy plants now banned by the FDA to ship products to the U.S. Story | More

Suggested Articles

Hospital-backed Civica Rx has struck a deal for a CDMO to help it develop its own brand of drugs, for which it will own the rights.

South Korea’s Celltrion, which has a massive biologics site in Songdo, has decided it is time to build some operations in China.

WuXi Biologics is taking control of a Bayer plant in Germany and agreed it could serve as a backup facility for supply of hemophilia drug Kovaltry.